The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at SITC 2026

MILWAUKEE, Oct. 29, 2026 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received almost 1,200 abstract submissions in 2026, and has announced titles and authors for the accepted Late-breaking Abstracts (LBA). Late-breaking Abstracts contain late-breaking data from interventional clinical trials in humans. The abstracts will be presented at SITC's upcoming 41^st Annual Meeting & Pre-Conference Programs taking place Nov. 4–8, 2026, in Phoenix, AZ and virtually.

SITC also invites you to attend the virtual press briefing of the society's 41^st Annual Meeting (SITC 2026) beginning at 12–1:30 p.m. MT on Wednesday, Nov. 4, 2026.

The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research. Data shared during the press briefing may be embargoed to a later date and time during the Annual Meeting and that information will be shared during the presentation. For more information, please review the SITC 2026 Media Policy.

The schedule of presentations and press briefing presenters are listed in order below:

• Abstract #553: Adoptive transfer of T cells engineered with mutant p53-specific TCRs for the treatment of metastatic solid epithelial cancers: interim report of ongoing phase II clinical trial
  • Presenter: Sanghyun Kim, PhD – National Cancer Institute
    
• Abstract #323: Adaptive anti-CAR immunity compromises the durability of GD2-CAR T cell therapy in diffuse midline glioma
  • Presenter: Kevin Reynolds, MD – Stanford Cancer Institute
• Abstract #566: OBX-115 TIL cell therapy in ICI-resistant advanced melanoma: Pooled safety and updated efficacy with minimally invasive tumor tissue procurement, low-dose lymphodepletion, and IL2-free regimen
  • Presenter: Rodabe Amaria, MD – The University of Texas MD Anderson Cancer Center
• Abstract #1176: Adoptive Immunotherapy with Effector T Lymphocytes that were Generated Following Cancer Neoantigen Vaccination of MGMT Unmethylated Glioblastoma Multiforme Patients is Associated with Survival Benefit
  • Presenter: Patrick Grogan, MD – Moffitt Cancer Center
• Abstract #828: Oncolytic Adenoviruses Induce Tertiary Lymphoid Structures in Brain Tumors to Promote Durable Antitumor Immunity
  • Presenter: Hong Jiang, PhD – The University of Texas MD Anderson Cancer Center
• Abstract #501: Phase 1b trial of intratumoral administration of the seasonal influenza vaccine in patients with melanoma
  • Presenter: Ian Garbarine, MD – The Ohio State University; The Ohio State University Comprehensive Cancer Center
• Abstract #1182: A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
  • Presenter: Justin Moser, MD – HonorHealth Research Institute
    
• Abstract #1185: Safety and Efficacy of Cesalatamig, a Novel PD-1/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1–Resistant/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1/2 Studies
  • Presenter: Kai He, MD, PhD – University of Texas Mays Cancer Center at San Antonio

ADDITIONAL DETAILS: 
Participating members of the media will have the opportunity to submit questions for up to three minutes following each presentation. To attend this press briefing, you must register as a member of the press for SITC 2026. To register, please visit https://www.sitcancer.org/2026/press/press-registration.
After registration is confirmed, you will receive instructions for the briefing. For more information regarding SITC 2026, please visit the Annual Meeting website at http://www.sitcancer.org/2026.

About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, Bluesky, Facebook and YouTube.

SOURCE Society for Immunotherapy of Cancer (SITC)